Most randomized controlled trials in chronic heart failure (HF) systematically excluded patients with severe renal dysfunction, often because of concern that the investigational treatment might cause further deterioration in kidney function. Yet these patients are at particularly high risk of adverse cardiovascular (CV) outcomes and might have much to gain from evidence-based therapies, if tolerated. International guidelines also express caution about the use of angiotensin-converting enzyme inhibitors (ACEi) and mineralocorticoid receptor antagonists (MRA) in patients with renal impairment, advising restriction of the use of ACEi and MRAs to those with estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m 2 (1, 2) . Heart failure patients with renal dysfunction are undertreated with respect to disease-modifying therapies, probably as a result of their exclusion from trials and the caution expressed in guidelines (3) . There have been a few small clinical trials in patients with end-stage renal disease with and without HF, but most did not investigate major fatal or nonfatal clinical events (4) . In this review, we analyze whether there is evidence (or not) that the key disease-modifying therapies used in HF are of benefit in patients with renal dysfunction.
Classification of Chronic Kidney Disease and Prevalence of Renal Dysfunction and Albuminuria in HF
The distribution of eGFR and prevalence of the different stages of chronic kidney disease (CKD) in the general population and in patients with heart failure with reduced (HFREF) and preserved ejection fraction (HFPEF) is presented in Table 1 (5, 6) . In both HFREF and HFPEF, renal dysfunction determined by reduced GFR is more prevalent compared with the general population. Patients with mild CKD (Kidney Disease Outcomes Quality Initiative [KDOQI] stage 1 and 2) have, generally, not been excluded from clinical trials and represent approximately one-third of patients included in randomized controlled trials. Similarly, approximately 30% to 35% of patients enrolled in recent clinical trials in HF had moderately severe (stage 3) CKD, although patients with severe renal dysfunction (stage 4 CKD) were usually excluded, except in studies in truly elderly patients where a greater proportion of patients (40% to 57%) had stage 3 to 4 CKD, in keeping with cohort studies and registries (7) (8) (9) (10) (11) (12) . Importantly, the KDOQI stages are not only dependent on eGFR but also require evidence of kidney damage (proteinuria or albuminuria) in stages 1 and 2 where eGFR is relatively preserved. Although just over 10% of the general population have albuminuria, approximately one-third of patients with both HFREF and HFPEF have increased urinary albumin excretion (Table 1) , and this has been linked to adverse clinical outcome. These data come from CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) and GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza dell'Insufficienza cardiac Heart Failure) trials (see the Online Appendix for a list of all trial acronyms), where none of the randomized treatments (candesartan, rosuvastatin or n-3 polyunsaturated fatty acids) showed a reduction in the level of urinary albumin excretion (13, 14) . On the basis of KDOQI recommendations, classification of CKD should take into account both eGFR and extent of albuminuria. The pathophysiology of concomitant cardiorenal failure has been reviewed extensively (15) . Figure 1 gives a simplified overview of possible cardiorenal interactions and where each of the therapies that will be discussed could influence these associations.
Single Renin Angiotensin Aldosterone System Blockade: ACE Inhibitors
Moderate renal dysfunctiondstage 3 CKD: eGFR 30 to 59 ml/min/1.73 m 2 . In the first major ACEi trial in patients with severe HF, the CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study) trial (enalapril; target dose 20 mg b.i.d., achieved 18.4 mg daily), most patients probably had a reduced GFR, because the mean serum creatinine (sCr) was 1.45 AE 0.05 mg/dl (128 AE 4 mmol/l), corresponding to an eGFR of approximately 47 ml/min/1.73 m 2 (on the basis of mean characteristics) ( Table 2) . In a subgroup analysis with patients stratified above and below the median sCr value 1.39 mg/dl (123 mmol/l, eGFR 49 ml/min/1.73 m 2 ), enalapril significantly improved outcome in patients with worse renal function but not in those with better renal function, although no formal interaction analysis was performed (16) . By contrast, another substudy showed that although there was a significant relative risk reduction of 45% in patients with sCr 140 mmol/l (1.58 mg/dl) (p ¼ 0.01), this effect was smaller (39%) and not significant in patients with sCr >140 mmol/l, although again no interaction analysis was performed (17) .
In the SOLVD Treatment (Studies of Left Ventricular Dysfunction Treatment) trial, enalapril (target dose 10 mg b.i.d., achieved 16.6 mg daily) significantly reduced the occurrence of CV death and HF hospital stays in the subgroup of patients with eGFR <60 ml/min/1.73 m 2 . There was no interaction between the beneficial effect of enalapril on mortality and morbidity and baseline eGFR (dichotomized at 60 ml/min/1.73 m 2 ) (18). In the ATLAS (Assessment of Treatment with Lisinopril and Survival) trial, which showed better outcomes with high-compared with low-dose lisinopril, there was no significant interaction between baseline sCr stratified at 1.5 mg/dl and the effect of treatment (19) . In the SAVE (Survival and Ventricular Enlargement) study, which included patients with left ventricular (LV) dysfunction after myocardial infarction (MI), baseline eGFR dichotomized at 60 ml/min/1.73 m 2 did not modify the beneficial effect of captopril on mortality and CV mortality/morbidity (20) . Severe renal dysfunctiondstage 4 and 5 CKD: eGFR <30 ml/min/1.73 m 2 . In the CONSENSUS trial, few patients (estimated 12%) with severe renal dysfunction (i.e., creatinine clearance <30 ml/min) were included (16, 21) . As mentioned in the preceding text, the subgroups of patients with sCr >140 mmol/l (eGFR <43 ml/min/1.73 m 2 ) did show a reduction in events, but this was not statistically significant, which was probably due to the low number (n ¼ 76) of patients. In the absence of an interaction analysis, it is likely that the overall effect of enalapril in the CONSENSUS trial also applied to this patient group (16, 17) . In the SOLVD Treatment study, the beneficial effect of enalapril was not affected by adjusting for baseline eGFR (18) . In patients with an eGFR <45 ml/min/1.73 m 2 (11% of patients), enalapril reduced both the risk of CV and HF hospital stays to the same extent as in other patients. However, an analysis of the effect of treatment in patients with an eGFR <30 ml/min/1.73 m 2 was not reported. There is reasonable and consistent evidence of improvement in outcome with ACEi in patients with HF (or LV systolic dysfunction after MI) and stage 3 CKD (Table 3) . It is possible that ACEi are also of benefit in patients with stage 4 to 5 CKD, but there are no conclusive data. Care should be taken to monitor renal function and electrolytes in these patients to achieve optimal benefit-risk ratio.
Angiotensin II Receptor Blockers
Stage 3 CKD. In the recent HEAAL (Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan) study, where high (150 mg daily) versus lower (50 mg daily) doses of losartan were evaluated, eGFR dichotomized at 75 ml/min/1.73 m 2 did not modify the beneficial effects of higher-dose losartan (22) . In the CHARM-alternative trial with candesartan (target dose 32 mg daily, achieved 23 mg daily), there was no significant interaction between baseline eGFR and the effect of candesartan treatment, suggesting that the benefit Figure 1 Pathophysiologic Pathways of the Interaction Between Heart Failure and Renal Dysfunction and the Effect of Evidence-Based Treatment There is limited evidence for the use of single ARB therapy in patients with stage 3 CKD, whereas there is an absence of data on the effect of ARB in severe renal dysfunction.
Dual RAAS Blockade: Add-On ARB Therapy Stage 3 CKD. In Val-HeFT (Valsartan Heart Failure Trial), valsartan (target dose 160 mg b.i.d., achieved dose 254 mg daily) reduced the composite mortality-morbidity endpoint but not the co-primary all-cause mortality endpoint. This benefit of treatment was consistent when baseline eGFR was dichotomized at 60 ml/min/1.73 m 2 (Table 4) (27) . Similarly, in the CHARM-Added trial, the beneficial effect of candesartan on the primary composite outcome of CV death or HF hospital stay was evident in patients with both preserved and reduced kidney function as determined by sCr </!2.0 mg/dl (28) . There was no Tables 2 and 3. significant interaction between baseline eGFR and this beneficial effect of candesartan (unpublished data). In contrast, in patients post-MI or at high CV risk, addition of an ARB to an ACEi does not improve outcome and might cause deterioration of renal function (29) . Stage 4 and 5 CKD. One study in hemodialysis patients with HF assessed the effect of addition of an ARB to standard therapy (100% ACEi, 60% beta-blocker, 50% digoxin) on outcome (30) . In that small trial (332 patients), telmisartan (target dose 80 mg daily, achieved dose 75 mg daily) significantly improved the primary endpoint of allcause mortality as well as the secondary endpoints of HF hospital stay or CV mortality.
Add-on ARB therapy should be considered in patients with chronic HF who do not tolerate an MRA, even if they have stage 3 CKD. Data in stage 4 to 5 CKD are limited to 1 study in hemodialysis patients but, in that study, did demonstrate benefit. Care should be taken to monitor renal function and electrolytes in a similar fashion as ACEi therapy.
Mineralocorticoid Receptor Antagonists
Stage 3 CKD. In RALES (Randomized Aldactone Evaluation Study) (target dose 50 mg daily, achieved 26 mg daily), a total of 48% of patients had eGFR <60 ml/min/1.73 m 2 (Table 5 ) (31) . In an interaction analysis, spironolactone improved outcome irrespective of renal function (32). The EPHESUS (Eplerenone Post-Acute Hospitalization and Survival Study in Heart Failure) trial enrolled patients with a reduced ejection fraction and evidence of HF (or diabetes mellitus) after recent MI (33) . There was an interaction between baseline sCr and the effect of treatment on all-cause mortality, whereby eplerenone was not associated with improved outcome in patients with sCr above 1.10 mg/dl. However, there was no such interaction for the co-primary endpoint of CV death or hospital stay. The most convincing and latest evidence comes from the recent EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trial, where 33% of patients had eGFR <60 ml/min/1.73 m 2 (7). The effect of eplerenone (target dose 50 mg daily, achieved 39 mg daily) on the primary composite endpoint of HF hospital stay or CV death was consistent in patients dichotomized at an eGFR <60 ml/min/1.73 m There is convincing evidence for a significant treatment benefit with the use of MRA in the setting of HF with moderate renal dysfunction (stage 3 CKD), but no data are available in stage 4 and 5 CKD.
Beta-Blockers
Stage 3 CKD. Despite the absence of robust evidence that beta-blockers worsen renal function, trials in HF have (34, 35) . Especially in the MERIT-HF study, the metoprolol/placebo hazard ratio was 0.41 (95% confidence interval: 0.25 to 0.68) in the 493 patients with eGFR <45 ml/min/1.73 m 2 (12% of the whole study population). This subgroup had a mean eGFR of 36.6 AE 6.8 ml/min/1.73 m 2 , which included patients with eGFR <30 ml/min/1.73 m 2 . In the SE-NIORS study, only 3.1% of patients had stage 4 CKD, but no subgroup analysis has been performed on these patients. As described earlier, in a meta-analysis of the CAPRI-CORN and COPERNICUS studies, there was no significant interaction between baseline eGFR and the effect of carvedilol, suggesting that carvedilol might improve outcome irrespective of renal function (37) . However, only 8% of all patients in these studies had stage 4 CKD. In 1 small trial in hemodialysis patients with HF, carvedilol significantly improved the secondary combined endpoint of allcause mortality and CV death (38) .
Large subgroup analyses from landmark trials have shown clear mortality and morbidity benefit for beta-blocker therapy in the general HF population with stage 3 CKD, and it seems likely that beta-blockers improve outcome in HF patients with severe renal dysfunction (stage 4 and 5 CKD).
Digoxin
Stage 3 CKD. Only 1 landmark placebo-controlled randomized trial, the DIG (Digitalis Investigation Group) study, examined the effects of adding digoxin (target dose individually determined, median achieved dose 0.25 mg daily, with 1% taking 0.5 mg daily) to treatment with a diuretic and ACEi in patients with HFREF (Table 7 ) (39). Shlipak et al. (40) examined whether baseline renal function modified the effect of digoxin and showed that the effect of this treatment was consistent across 3 eGFR categories studied (i.e., <30, 30 to 60, and >60 ml/min/1.73 m 2 ). Stage 4 and 5 CKD. There was no interaction between baseline renal function and the effect of digoxin in 218 patients with stage 4 CKD in the DIG study. Moreover, in another analysis of the DIG study, digoxin reduced mortality in 289 patients with sCr >2.0 mg/dl, with a significant interaction between the effect of digoxin and baseline sCr, with a stronger effect of digoxin in patients with higher baseline sCr (40) . Given the renal excretion of digoxin and the risk of digoxin intoxication especially in renal insufficiency, careful monitoring or renal function and especially potassium, in addition to digoxin concentration monitoring, is indicated with the use of digoxin. This is supported by findings in the DIG study, where patients with eGFR <30 ml/min/1.73 m 2 were treated with the lowest doses of digoxin but still had the highest serum digoxin levels.
Digoxin might be considered in patients with stage 3 to 5 CKD, with careful monitoring of digoxin concentrations and electrolytes.
Ivabradine
The effect of ivabradine on mortality and morbidity in patients with LV systolic dysfunction was studied in 2 studies (SHIFT [Systolic Heart failure treatment with the IF inhibitor ivabradine Trial] and BEAUTIFUL [Morbidity-mortality Evaluation of the If inhibitor ivabradine in patients with coronary disease and left-ventricular dysfunction] trials), but a renal subgroup analysis has not been published in either (Table 7) (41, 42) . Considering the pharmacological effect of ivabradine, it is unlikely to cause deterioration in renal function, and because renal clearance accounts for 20% of ivabradine clearance, there is no need for dose adjustment in patients with renal impairment, although there are no data in patients with creatinine clearance <15 ml/min.
Hydralazine and Isosorbide-Dinitrate
No renal subgroup analyses are available from the V-HeFT (Vasodilator Heart Failure Trial) studies (43, 44) . A-HeFT (African-American Heart Failure Trial), in AfricanAmerican HF patients, did not show significant interaction between a history of "renal insufficiency" and the effect of hydralazine and isosorbide-dinitrate (H-ISDN) therapy (target dose 225 mg hydralazine/120 ISDN, achieved dose in 68%) (44) .
Diuretics
Diuretics are indicated in patients with symptoms and/or signs of congestion (1,2). Current guidelines advocate using the minimum dose necessary to achieve "dry weight" and to reduce the dose, if possible, so as to prevent dehydration and deterioration in renal function. Paradoxically, it has recently been recognized that diuretics might improve renal function if there is renal venous congestion, emphasizing that diuretic needs might change according to the clinical status of patients and that dose should be fine-tuned on an individual basis (45) . No specific data are available that show improvement in outcome in patients with HF and renal impairment, and only 1 small meta-analysis showed a possible prognostic benefit of loop diuretics in the general HF population. There is also a call for a shift toward novel loop diuretics such as torsemide, because small randomized trials might suggest improvement in clinical outcome, but to date the pooling of studies does not suggest improved outcome in the entire HF population (46) (47) (48) . Therefore, start and titration of diuretic therapy is dependent on individual patient characteristics, including vital signs, symptoms, and signs of congestion and baseline renal function.
Implantable-Cardioverter Defibrillator Therapy
Approximately 8 trials examined the role of implantablecardioverter defibrillator (ICD) therapy for primary (49) (50) (51) (52) and secondary (53-56) prevention of fatal ventricular arrhythmia in ischemic and nonischemic populations (Table 8) . Although renal dysfunction was not an exclusion criterion in these trials, baseline renal function was reported only in the MADIT (Multicenter Automatic Defibrillator Implantation Trial), MADIT II (Multicenter Automatic Defibrillator Implantation Trial II), and SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) (Table 8 ) (49, 50, 52) . Only 1 subgroup analysis has been published looking at patients with stage 3 CKD. This subgroup analysis from the MADIT II study showed beneficial effects of ICD therapy in all patients, including those with eGFR between 35 and 60 ml/min/1.73 m 2 , without evidence of significant interaction between ICD therapy and renal function (57) . Numerically, the beneficial effect of ICD therapy was not observed in 80 patients with eGFR <35 ml/min/1.73 m 2 . However, the interaction between baseline eGFR and the effect of ICD therapy was not statistically different, suggesting that the overall effect of the study also applied to this specific patient cohort (57) .
Patients with stage 3 to 5 CKD were not excluded from ICD trials, and the treatment effect seems independent of renal function. Therefore these patients should be considered for ICD therapy.
Cardiac Resynchronization Therapy
Stage 3 CKD. The landmark CARE-HF (Cardiac Resynchronization Heart Failure) trial provides the best data on the effects of cardiac resynchronization therapy (CRT) in patients with stage 3 CKD (Table 9 ) (58) . Overall, CRT led to a 37% relative risk reduction in all-cause mortality in the CARE-HF trial. There was no interaction between baseline GFR and the effect of treatment (i.e., CRT led to a relative risk reduction in mortality of 33% in patients with CKD). In patients with milder symptoms and stage 3 CKD in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization) trial, the benefit of CRT-D, compared with an ICD, was similar to that in the entire population, with no interaction between renal function and effect of treatment (59, 60) . In the RAFT (Resynchronization Defibrillation for Ambulatory Heart Failure Trial), CRT improved outcome in patients with and without CKD, without a significant interaction between baseline renal function and the effect of treatment (61) . Importantly, almost 50% of patients had eGFR <60 ml/min/1.73 m 2 in the RAFT and MADIT-CRT studies, suggesting that the overall findings are generalizable. From a pathophysiological perspective, CRT improves cardiac output and thereby probably improves renal perfusion and function (62) . This was confirmed in a systematic review of CRT in CKD, where CRT not only improved eGFR but also clinical outcome (63) . Stage 4 and 5 CKD. Although patients with a sCr >3.0 mg/dl were excluded from the MADIT-CRT and MIRACLE (Multicenter InSync Randomized Clinical Evaluation) trials, a large proportion had CKD, defined as an eGFR <60 ml/min/1.73 m 2 (as did many in the CARE-HF (Cardiac Resynchronization Heart Failure) and RAFT studies), meaning that some patients with stage 4 and 5 CKD were included in these trials (59, 64) . However, the effect of therapy in these patients has not been reported (58, 59, 61, 64) .
There is convincing evidence for the use of CRT therapy in patients with mild to severe HF and stage 3 CKD, whereas there are no specific data on the effect of CRT in stage 4 to 5 CKD.
Absolute and Relative Risk Reduction in Patients With Stage 3 to 5 CKD
Because patients with stage 3 to 5 CKD have much higher rates of death and hospital stay than patients with little or no renal dysfunction, the absolute risk reduction with the treatments discussed earlier is potentially much greater in the former patients. For instance, in the MERIT-HF study, the absolute risk reductions with metoprolol in patients with an eGFR >60, 45 to 60, and <45 ml/min/1.73 m 2 for allcause mortality were 2.5%, 3.95%, and 12.6%, respectively. This resulted in a number needed to treat for 18 months of 40, 26, and 8 to prevent 1 death for each eGFR category. Damman (32, (65) (66) (67) (68) . This concern might be amplified by the perception that worsening renal function (WRF) is associated with increased mortality in patients with HF, although this is not entirely correct, as explained in the following (69) . During initiation of an ACEi or ARB, between 10% and 35% of patients experience some increase in sCr (Table 10 ). In the CONSENSUS trial, the incidence of a substantial increase in sCr (30% to 100%) was 24%, whereas 11% even had more than doubling of sCr (70) . Early WRF occurred in as much as 10% of patients in the SOLVD studies (66) . In the CHARM program, the incidence of doubling of sCr was higher in the candesartan (5.5% to 7%) than in the placebo groups (1.6% to 6%) (71, 72) . In head-to-head comparisons, the risk of WRF is similar with ARBs as with ACEi, and the frequency of WRF is higher on higherdosage regimens of ARB or ACEi (19, 24, 26, 73) . The effect of MRAs on change in eGFR in clinical trials showed similarities with that observed in trials with ACEi and ARBs. After an initial fall in eGFR, the gradual decline in renal function over time with an MRA runs parallel to that in the placebo group (67) . In clinical trials at least, the incidence of clinically important renal dysfunction seems to have been similar in the placebo and MRA group (e.g., approximately 2% in the EMPHASIS-HF trial) (7) .
Recently, it has become clear that deterioration in renal function induced by inhibition of the RAAS does not have the same adverse prognostic implications as other types of WRF in HF. For example, WRF after initiation of enalapril in the SOLVD trial did not confer increased risk of death, compared with an increase in creatinine in the placebo group (66) . Even in the CONSENSUS trial, where most patients experienced an increase in creatinine with enalapril, ACE inhibition led to a striking improvement in survival (68) . Similarly, in the RALES trial, spironolactone caused more WRF than placebo, but WRF was not associated with worse outcome in the spironolactone group, in contrast to WRF occurring in the placebo group (32) .
Clearly, however, an extreme deterioration in renal function is not acceptable and is dangerous. However, the exact degree of WRF that should mandate dose-reduction or discontinuation of RAAS blockade is uncertain. From the large clinical trials, a decrease in eGFR of even 20% to 30% with ACEi, ARB, or MRA therapy with these treatments does not seem to attenuate the reduction in CV event rates. Therefore it seems that, although WRF (in these magnitudes) is unwanted, it should not be a reason to withhold or discontinue therapy. The latest guidelines suggest that an increase in creatinine of up to 50% above baseline or to an absolute 266 mmol/l (3 mg/dl)/eGFR <25 ml/min/1.73 m 2 , whichever is the smaller, is acceptable (1, 2) . If sCr increases with a RAAS blocker, nephrotoxic drugs should be stopped if possible and/or the dose of the diuretic reduced. If these interventions are not relevant, not possible, or have no effect and renal function deteriorates to the extent described in the preceding text, the dose of the RAAS-inhibitor should be halved and sCr checked within 2 weeks. If the sCr increases by >100% or to >310 mmol/l (3.5 mg/dl)/eGFR <20 ml/min/1.73 m 2 , RAAS blockade should be stopped. Other therapies. Beta-blockers have little if any effect on renal function in patients with HF. An analysis from the SOLVD trial indicated that beta-blocker treatment at baseline was associated with a reduced risk of deterioration in renal function during follow-up, although this was an observational analysis, and patients had not been randomized to a betablocker or placebo (74) . As discussed earlier, diuretics can cause hypotension, dehydration, and renal dysfunction (75) . Therefore, diuretic dose should be altered on the basis of individual symptoms, signs, and electrolytes, including renal function. Other therapies, including ivabradine, digoxin, and H-ISDN, are not known to cause renal dysfunction.
RAAS-Inhibitors: Hyperkalemia
Patients with CKD are at increased risk for the development of hyperkalemia, and this risk is further increased by the introduction of RAAS inhibitors. Table 10 reviews the incidence of hyperkalemia in different clinical trials. Hyperkalemia is most frequently observed with the initiation of MRA therapy, but 6.4% of patients in the SOLVD Treatment trial were reported to have developed hyperkalemia with enalapril therapy. In the large MRA studies, the incidence of hyperkalemia ranged from 2% to 11.8%, depending on the definition (7, 31, 33) . Importantly, no deaths attributable to hyperkalemia were reported in any of the MRA studies. Hyperkalemia occurred mostly in patients with low baseline eGFR, in those with WRF during therapy, and most importantly in those receiving spironolactone or eplerenone in the RALES and EMPHASIS-HF trials, respectively (32, 76) . A stringent monitoring of potassium levels in patients started on an MRA regimen seems warranted. For instance, in the EMPHASIS-HF trial, eplerenone was started only if the serum potassium level was no more than 5.0 mmol/l. Thereafter, the dose of eplerenone was decreased if the serum potassium level was 5.5 to 5.9 mmol/l during follow-up and withheld if the serum potassium rose above 6.0 mmol/l. Reassessment of potassium was done 72 h after dose reduction, and patients were re-challenged with eplerenone, only if potassium levels were below 5.0 mmol/l. This regimen was found to be highly effective, because the incidence of hyperkalemia leading to study drug withdrawal was not different from placebo (7). The new American College of Cardiology Foundation/American Heart Association guidelines support these recommendations (2) . These findings highlight the importance of both hyperkalemia and rigorous 
Renal Excretion of Pharmacological Therapies
Finally, the dose of several evidence-based treatments should be adjusted according to GFR, because their clearance from the circulation depends on renal function (Table 11 ). The dose of ACEi should be halved in patients in stage 4 and 5 CKD or given every other day in patients on dialysis. The same advice applies to MRAs, although eplerenone is not indicated in patients with eGFR <30 ml/min/1.73 m 2 .
Although most beta-blockers are cleared from the circulation to some extent by the kidneys, dose reduction is only required in patients with a severely reduced eGFR to achieve similar heart rate reductions compared with patients with normal renal function.
Conclusions: Recommendations for Clinical Practice
In general, the recommendations for medical therapy in HF patients with concomitant renal dysfunction are not qualitatively different from those in patients with preserved (Fig. 2) (1,2). Although there is less robust evidence of benefit in HF patients with a reduced GFR, subgroup analyses of the trials testing the major classes of drugs (ACEi, beta-blockers, MRAs, and ARBs) and devices (ICD/CRT) suggest that the relative risk reductions are similar (and absolute risk reductions greater), although these therapies might cause unwanted effects. Especially in patients with stage 4 and 5 CKD, care should be taken to assess whether possible beneficial effects might outweigh the potential risks associated with the initiation of this therapy. In all patients, frequent assessment of renal function and electrolytes (potassium) is essential to guide dose adjustment and (dis)continuation of therapy. Treatment discontinuation might be temporary and should follow the algorithms successfully implemented in clinical trials (e.g., the CHARM/EMPHASIS-HF trials), and this close monitoring is often best facilitated within disease management programs. Importantly, attempts should be made to reinstate the evidence-based therapy, once either renal function has improved or stabilized. For any HF patient with renal dysfunction (i.e., a patient with a greatly increased risk of death or HF hospital stay in the immediate future), the focus should be not only on survival but also on quality of life and time spent out of hospital. Considering that most evidence-based therapies are even more effective in reducing hospital stay than they are at decreasing mortality, each should at least be considered in patients with stage 3 to 5 CKD but their use must also be individualized. 
